BRPI0917491A2 - tratamento de hipertensao arterial pulmonar - Google Patents

tratamento de hipertensao arterial pulmonar

Info

Publication number
BRPI0917491A2
BRPI0917491A2 BRPI0917491A BRPI0917491A BRPI0917491A2 BR PI0917491 A2 BRPI0917491 A2 BR PI0917491A2 BR PI0917491 A BRPI0917491 A BR PI0917491A BR PI0917491 A BRPI0917491 A BR PI0917491A BR PI0917491 A2 BRPI0917491 A2 BR PI0917491A2
Authority
BR
Brazil
Prior art keywords
arterial hypertension
pulmonary arterial
hypertension treatment
treatment
pulmonary
Prior art date
Application number
BRPI0917491A
Other languages
English (en)
Portuguese (pt)
Inventor
Deborah Quinn
Steve Pascoe
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41137217&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0917491(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0917491A2 publication Critical patent/BRPI0917491A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BRPI0917491A 2008-08-13 2009-08-11 tratamento de hipertensao arterial pulmonar BRPI0917491A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8838208P 2008-08-13 2008-08-13
US16450109P 2009-03-30 2009-03-30
PCT/US2009/053358 WO2010019540A1 (en) 2008-08-13 2009-08-11 Treatment of pulmonary arterial hypertension

Publications (1)

Publication Number Publication Date
BRPI0917491A2 true BRPI0917491A2 (pt) 2015-12-01

Family

ID=41137217

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0917491A BRPI0917491A2 (pt) 2008-08-13 2009-08-11 tratamento de hipertensao arterial pulmonar

Country Status (16)

Country Link
US (1) US20110190313A1 (cg-RX-API-DMAC7.html)
EP (1) EP2315592A1 (cg-RX-API-DMAC7.html)
JP (1) JP2011530607A (cg-RX-API-DMAC7.html)
KR (1) KR20110053354A (cg-RX-API-DMAC7.html)
CN (1) CN102123711A (cg-RX-API-DMAC7.html)
AU (1) AU2009282104A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0917491A2 (cg-RX-API-DMAC7.html)
CA (1) CA2732789A1 (cg-RX-API-DMAC7.html)
CL (1) CL2011000295A1 (cg-RX-API-DMAC7.html)
IL (1) IL210922A0 (cg-RX-API-DMAC7.html)
MA (1) MA32617B1 (cg-RX-API-DMAC7.html)
MX (1) MX2011001668A (cg-RX-API-DMAC7.html)
NZ (1) NZ590839A (cg-RX-API-DMAC7.html)
RU (1) RU2011109078A (cg-RX-API-DMAC7.html)
TW (1) TW201010999A (cg-RX-API-DMAC7.html)
WO (1) WO2010019540A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2671029A1 (en) 2009-06-30 2010-12-30 James S. Baldassarre Methods of treating term and near-term neonates having hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension
EP3007689B1 (en) 2013-01-10 2018-03-07 Pulmokine, Inc. Non-selective kinase inhibitors
JP6799201B2 (ja) * 2013-07-31 2020-12-16 アヴァリン ファーマ インク． エアロゾルチロシンキナーゼ阻害剤の化合物、及びその使用
US9925184B2 (en) 2013-10-11 2018-03-27 Pulmokine, Inc. Spray-dry formulations
AU2017348354B2 (en) 2016-10-27 2023-06-15 Pulmokine, Inc. Combination therapy for treating pulmonary hypertension
CN110198718B (zh) 2016-11-08 2023-01-10 里亚塔医药控股有限责任公司 使用甲基巴多索隆或其类似物治疗阿尔波特综合征的方法
WO2019157337A1 (en) * 2018-02-08 2019-08-15 Pulmokine, Inc. Formulations of kinase inhibitors and prostanoids
CN114514016A (zh) 2019-05-16 2022-05-17 埃渃维特治疗学公司 伊马替尼调配物、制造和其用途
US11464776B2 (en) 2019-05-16 2022-10-11 Aerovate Therapeutics, Inc. Inhalable imatinib formulations, manufacture, and uses thereof
WO2021108303A1 (en) * 2019-11-25 2021-06-03 PHPrecisionMed, LLC Pharmaceutical compositions for the treatment of pulmonary hypertension
AU2021339756A1 (en) * 2020-09-11 2023-04-13 Pulmosim Therapeutics Llc Compositions and methods for treating or preventing pulmonary hypertension
JP2023550407A (ja) 2020-11-17 2023-12-01 ユナイテッド セラピューティクス コーポレイション 肺高血圧向けの吸入式イマチニブ

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
GB0215676D0 (en) * 2002-07-05 2002-08-14 Novartis Ag Organic compounds
AU2003272007A1 (en) * 2002-10-25 2004-05-13 The Administrators Of The Tulane Educational Fund Use of n-5-4-(4-methylpiperaziomethyl)-benzoylamido!-2-methylphenyl!-4-(3-pyridyl)2-pyridine-amine for the treatment of pulmonary hypertension
GB0325031D0 (en) * 2003-10-27 2003-12-03 Novartis Ag Organic compounds
MX2007009135A (es) * 2005-01-28 2007-09-06 Novartis Ag Uso de pirimidilaminobenzamidas para el tratamiento de enfermedades que responden a la modulacion de la actividad de la cinasa tie-2.
KR101519311B1 (ko) * 2005-05-02 2015-05-11 노파르티스 아게 과호산구성 증후군을 위한 피리미딜아미노벤즈아미드 유도체
CA2629132C (en) * 2005-12-06 2014-05-27 Novartis Ag Pyrimidylaminobenzamide derivatives for the treatment of neurofibromatosis
US20100048539A1 (en) * 2006-11-03 2010-02-25 Irm Llc Compounds and compositions as protein kinase inhibitors

Also Published As

Publication number Publication date
JP2011530607A (ja) 2011-12-22
WO2010019540A1 (en) 2010-02-18
IL210922A0 (en) 2011-04-28
TW201010999A (en) 2010-03-16
CN102123711A (zh) 2011-07-13
MX2011001668A (es) 2011-03-25
US20110190313A1 (en) 2011-08-04
CL2011000295A1 (es) 2011-07-15
KR20110053354A (ko) 2011-05-20
EP2315592A1 (en) 2011-05-04
MA32617B1 (fr) 2011-09-01
RU2011109078A (ru) 2012-09-20
CA2732789A1 (en) 2010-02-18
AU2009282104A1 (en) 2010-02-18
NZ590839A (en) 2013-02-22

Similar Documents

Publication Publication Date Title
BRPI0917491A2 (pt) tratamento de hipertensao arterial pulmonar
EP2333141A4 (en) DRIER
EP2277424A4 (en) HAND DRYER
EP2332943A4 (en) NOVEL CONDENSATE AMINODIHYDROTHIAZINE DERIVATIVE
EP2244670A4 (en) INTERSPINED DISTANCE MEMBER
EP2242446A4 (en) PARTIAL SLEEVE
BRPI0916763A2 (pt) dialisador
DK2201858T3 (da) Hårtørrer
BRPI0915524A2 (pt) conjunto de aerofólio
EP2256192A4 (en) CATALASE WITH TEMPERATURE TOLERANCE
BRPI0906807A2 (pt) Fibra monofilamentar
EP2264505A4 (en) LENS LENS
DK1987765T3 (da) Oximeter
DK2318378T3 (da) Quinazolin-derivater
DK2300238T3 (da) Skyggebillede-sikkerhedstræk
BRPI0819362A2 (pt) Cesta-peneira
EP2337157A4 (en) CONNECTOR
BRPI0915442A2 (pt) tamis melhorado
BRPI0912547A2 (pt) aba de fixação
BRPI0917718A2 (pt) calçado
HRP20160577T1 (hr) Liječenje osteoartritisa
ATE546371T1 (de) Holzbottich
EP2344695A4 (en) WHITENING METHOD
FI20080312L (fi) Harvesteri
ES1069830Y (es) Yurta moderna

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2372 DE 21-06-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.